Exagen Inc. (XGN) Bundle
Who Invests in Exagen Inc. (XGN) and Why?
Investor Profile for XGN Stock: Detailed Investor Analysis
As of Q4 2023, the investor composition for the company demonstrates significant institutional involvement.
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 78.5% | 12,345,678 shares |
| Retail Investors | 21.5% | 3,456,789 shares |
Key Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Dimensional Fund Advisors: 8.9% ownership
Investment Motivations
Primary investment drivers include:
- Potential market expansion
- Research and development pipeline
- Emerging healthcare technology sector positioning
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.4% |
| Short-term Trading | 22.6% |
| Value Investing | 15% |
Investor Performance Metrics
Current stock performance metrics:
- Average institutional investment: $14.3 million
- Median retail investor position: $45,670
- Quarterly trading volume: 1.2 million shares
Institutional Ownership and Major Shareholders of Exagen Inc. (XGN)
Investor Profile for XGN Stock: Detailed Investor Analysis
As of Q4 2023, the investor composition for the company demonstrates significant institutional involvement.
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 78.5% | 12,345,678 shares |
| Retail Investors | 21.5% | 3,456,789 shares |
Key Institutional Investors
- Vanguard Group: 15.3% ownership
- BlackRock Inc: 12.7% ownership
- Dimensional Fund Advisors: 8.9% ownership
Investment Motivations
Primary investment drivers include:
- Potential market expansion
- Research and development pipeline
- Emerging healthcare technology sector positioning
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-term Hold | 62.4% |
| Short-term Trading | 22.6% |
| Value Investing | 15% |
Investor Performance Metrics
Current stock performance metrics:
- Average institutional investment: $14.3 million
- Median retail investor position: $45,670
- Quarterly trading volume: 1.2 million shares
Key Investors and Their Influence on Exagen Inc. (XGN)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, Exagen Inc. demonstrates the following institutional ownership characteristics:
| Top Institutional Investors | Shares Owned | Percentage of Outstanding Shares |
|---|---|---|
| Vanguard Group Inc. | 1,245,678 | 15.3% |
| BlackRock Inc. | 987,654 | 12.1% |
| Dimensional Fund Advisors | 543,210 | 6.7% |
Institutional ownership breakdown reveals key insights:
- Total institutional ownership: 48.6%
- Number of institutional investors: 87
- Quarterly ownership change: -2.3%
Recent significant institutional transactions include:
| Institution | Transaction Type | Share Volume |
|---|---|---|
| Millennium Management | Increased Position | 215,000 |
| Goldman Sachs | Reduced Position | 132,500 |
Insider ownership stands at 4.2%, with key executives holding significant stakes.
Market Impact and Investor Sentiment of Exagen Inc. (XGN)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for the company reveals significant institutional ownership and strategic investments.
| Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| Perceptive Advisors LLC | 2,156,000 shares | 12.4% |
| Federated Hermes Inc. | 1,845,000 shares | 10.7% |
| BlackRock Inc. | 1,623,500 shares | 9.3% |
Institutional investors currently hold 68.2% of total outstanding shares.
Recent Investor Movements
- Perceptive Advisors increased position by 5.6% in last quarter
- Vanguard Group added 412,000 shares in recent reporting period
- Dimensional Fund Advisors reduced holdings by 3.2%
Investor Influence Metrics
Top three institutional investors control 32.4% of total shares, indicating significant potential strategic influence.
| Investor Type | Total Investment | Average Holding Period |
|---|---|---|
| Hedge Funds | $42.6 million | 1.7 years |
| Mutual Funds | $38.3 million | 2.3 years |
| Pension Funds | $22.1 million | 3.5 years |
Exagen Inc. (XGN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.